Pharmaceutical Manufacturers Attempt to Safeguard Business Continuity from Potential Threats and Disasters to Production
CHAPEL HILL, N.C. – July 27, 2012. Bio-Pharmaceutical and medical device leaders are re-evaluating their crisis management preparation and processes in light of recent major disasters that have disrupted supply chains and global manufacturing operations, according to analysts at research and consulting firm Best Practices, LLC.
Although training frequency goes hand-in-hand with response effectiveness, more than 60% of companies conduct emergency response training only once or twice a year – or not at all. As a result, many companies are trying to safeguard their supply chain and optimize crisis management capabilities in order to continuously meet quality standards and regulations.
To identify how other world-class companies plan, prevent, prepare and respond to potential threats, Best Practices, LLC has published a new study: “Best Practices in Crisis Management & Business Continuity for BioPharma Manufacturing and Supply Chain Operations.”
This study comprises key performance metrics around supply chain operations, sole-source suppliers, and future trends in contingency planning. Biopharmaceutical manufacturing leaders can apply this research to best reduce risk and enhance response time in the quickly changing healthcare industry.
Key Topics of this report include:
- Business Continuity Group Structure & Leadership
- Assessing Risks & Prioritizing Response
- Securing Your Supply Chain to Safeguard Customers and the Company
- Working with Sole-Source or Strategic Suppliers
- Creating a Business Resiliency Framework: The Next Generation
- Developing a Prevention Mind-set and Fast Response
- Using Backups & Redundancy Management
- Communication During a Crisis
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1163.htm.
The 110-page report contains over 500 metrics and 55 narratives to provide biopharmaceutical leaders with an evidence-based understanding of how other companies in the pharmaceutical and medical device industries are attempting to align their resources and activities to ensure the continuity of their manufacturing operations.
While previous studies have captured key metrics to identify optimal resource levels for maximum competitiveness, unplanned events can severely disrupt the effectiveness of the industry’s proven business model - a fact pressing executives to reprioritizing business objectives and responsibilities that will be most beneficial to growth and sustainability.
For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at email@example.com.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC’s clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.